Study Title and Description
Saccharomyces cerevisiae fungemia: an emerging infectious disease.
Key Questions Addressed
|8||Key Question 8 - Case studies/series and potential harms of nonstandard interventions for CDI|
Primary Publication Information
|Title||Saccharomyces cerevisiae fungemia: an emerging infectious disease.|
|Author||Muñoz P., Bouza E., Cuenca-Estrella M., Eiros JM., Pérez MJ., Sánchez-Somolinos M., Rincón C., Hortal J., Peláez T.|
|Country||Department of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid, Spain. firstname.lastname@example.org|
Pubmed ID: 15889360
Secondary Publication Information
There are currently no secondary publications defined for this study.
Extraction Form: Key Question 4 - Case studies/series and potential harms of nonstandard interventions for CDI (Table C11)
|Question... Follow Up||Answer||Follow-up Answer|
|Subject/Study Details||Case studies + Retrospective chart review of ICU pts + review of 57 patients literature review. 3 ICU patients 3 ICU patients (females in 70s) with S. cerevisiae fungemia Charts of 41 (with 14 ICU) patients over 1 month of fungemia outbreak were reviewed|
|Interventions||Probiotic: 3 cases were treated with Ultralevura for C. difficile infection 2/41 patients without fungemia received probiotic|
|Clinical Diarrhea Outcomes|
|C. difficile Toxin, C. difficile Culture, or Other||Probiotic cultures grew heavy yeast (>1 million cfu/ml) Mortality: 28% (17/60)|
|Adverse Effects (AE) Harms||60 patients total with fungemia, 28/47 (60%) in ICU, 26 (46%) were treated with the probiotic|
Results & Comparisons
No Results found.